La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Stoke Therapeutics Gestione
Gestione criteri di controllo 4/4
Stoke Therapeutics' Il CEO è Ed Kaye, nominato in Oct2017, e ha un mandato di 6.83 anni. la retribuzione annua totale è $ 3.53M, composta da 17.7% di stipendio e 82.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.051% delle azioni della società, per un valore di $ 394.98K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.6 anni e 5.9 anni.
Informazioni chiave
Ed Kaye
Amministratore delegato
US$3.5m
Compenso totale
| Percentuale dello stipendio del CEO | 17.7% |
| Mandato del CEO | 6.8yrs |
| Proprietà del CEO | 0.05% |
| Durata media del management | 3.6yrs |
| Durata media del Consiglio di amministrazione | 5.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap
Dec 14Stoke Therapeutics prices $97.5M public offering
Nov 20Stoke Therapeutics -2.7% AH, proposes public offering
Nov 18We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Nov 18Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$4m | US$626k | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$99m |
| Dec 31 2022 | US$6m | US$596k | -US$101m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$9m | US$568k | -US$86m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$5m | US$549k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$668k | US$477k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$1m | US$464k | -US$13m |
Compensazione vs Mercato: La retribuzione totale di Ed ($USD 3.53M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 3.30M ).
Compensazione vs guadagni: La retribuzione di Ed è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Ed Kaye (75 yo)
6.8yrs
Mandato
US$3,533,210
Compensazione
Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$3.53m | 0.051% $ 400.6k | |
| Co-Founder & Independent Director | no data | US$198.33k | 0.77% $ 6.0m | |
| Chief Medical Officer | 6.8yrs | US$1.65m | 0.0047% $ 36.9k | |
| Co-Founder & Senior VP of Discovery Research | no data | Nessun dato | Nessun dato | |
| Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
| Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| Corporate Secretary & General Counsel | 3.6yrs | Nessun dato | 0.0049% $ 38.5k | |
| Chief Communications Officer | 3.6yrs | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 4.8yrs | Nessun dato | Nessun dato | |
| Chief Business Officer | less than a year | US$869.86k | 0% $ 0 | |
| Chief Regulatory Officer | 5.7yrs | Nessun dato | Nessun dato | |
| Chief Commercial Officer | less than a year | Nessun dato | Nessun dato |
3.6yrs
Durata media
54.5yo
Età media
Gestione esperta: Il team dirigenziale di STOK è considerato esperto (durata media dell'incarico 3.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$3.53m | 0.051% $ 400.6k | |
| Co-Founder & Independent Director | 10.2yrs | US$198.33k | 0.77% $ 6.0m | |
| Independent Chairman of the Board | 9.1yrs | US$237.33k | 3.56% $ 27.8m | |
| Independent Director | 8.9yrs | US$198.33k | 0.034% $ 266.8k | |
| Independent Director | less than a year | US$394.03k | 0% $ 0 | |
| Independent Director | 4yrs | US$199.33k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$206.83k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$209.33k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$211.83k | 0.060% $ 471.0k |
5.9yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di STOK sono considerati esperti (durata media dell'incarico 5.9 anni).